Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe

M. Schlander, C.C. Adarkwah, A. Gandjour

Research output: Contribution to journalArticleAcademicpeer-review

3 Citations (Scopus)

Abstract

Background/aim: Ultra-orphan diseases (UODs) have been defined by a prevalence of less than 1 per 50,000 persons. However, little is known about budget impact of ultra-orphan drugs. Methods: For analysis, the budget impact analysis (BIA) had a time horizon of 10 years (2012-2021) and a pan-European payer's perspective, based on prevalence data for UODs for which patented drugs are available and/or for which drugs are in clinical development. Results: A total of 18 drugs under patent protection or orphan drug designation for non-oncological UODs were identified. Furthermore, 29 ultra-orphan drugs for non-oncological diseases under development that have the potential of reaching the market by 2021 were found. Total budget impact over 10 years was estimated to be (sic)15,660 and (sic)4965 million for approved and pipeline ultra-orphan drugs, respectively (total: (sic)20,625 million). Conclusion: The analysis does not support concerns regarding an uncontrolled growth in expenditures for drugs for UODs.

Original languageEnglish
Pages (from-to)171-179
Number of pages9
JournalExpert Review of Pharmacoeconomics & Outcomes Research
Volume15
Issue number1
DOIs
Publication statusPublished - Feb 2015

Keywords

  • budget impact analysis
  • drugs
  • Europe
  • non-oncological diseases
  • ultra-orphan
  • TASK-FORCE
  • RARE
  • PRINCIPLES
  • DISORDERS

Cite this

@article{b81f05f920b144ad834627ea5e931b72,
title = "Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe",
abstract = "Background/aim: Ultra-orphan diseases (UODs) have been defined by a prevalence of less than 1 per 50,000 persons. However, little is known about budget impact of ultra-orphan drugs. Methods: For analysis, the budget impact analysis (BIA) had a time horizon of 10 years (2012-2021) and a pan-European payer's perspective, based on prevalence data for UODs for which patented drugs are available and/or for which drugs are in clinical development. Results: A total of 18 drugs under patent protection or orphan drug designation for non-oncological UODs were identified. Furthermore, 29 ultra-orphan drugs for non-oncological diseases under development that have the potential of reaching the market by 2021 were found. Total budget impact over 10 years was estimated to be (sic)15,660 and (sic)4965 million for approved and pipeline ultra-orphan drugs, respectively (total: (sic)20,625 million). Conclusion: The analysis does not support concerns regarding an uncontrolled growth in expenditures for drugs for UODs.",
keywords = "budget impact analysis, drugs, Europe, non-oncological diseases, ultra-orphan, TASK-FORCE, RARE, PRINCIPLES, DISORDERS",
author = "M. Schlander and C.C. Adarkwah and A. Gandjour",
year = "2015",
month = "2",
doi = "10.1586/14737167.2015.965156",
language = "English",
volume = "15",
pages = "171--179",
journal = "Expert Review of Pharmacoeconomics & Outcomes Research",
issn = "1473-7167",
publisher = "Routledge/Taylor & Francis Group",
number = "1",

}

Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe. / Schlander, M.; Adarkwah, C.C.; Gandjour, A.

In: Expert Review of Pharmacoeconomics & Outcomes Research, Vol. 15, No. 1, 02.2015, p. 171-179.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Budget impact analysis of drugs for ultra-orphan non-oncological diseases in Europe

AU - Schlander, M.

AU - Adarkwah, C.C.

AU - Gandjour, A.

PY - 2015/2

Y1 - 2015/2

N2 - Background/aim: Ultra-orphan diseases (UODs) have been defined by a prevalence of less than 1 per 50,000 persons. However, little is known about budget impact of ultra-orphan drugs. Methods: For analysis, the budget impact analysis (BIA) had a time horizon of 10 years (2012-2021) and a pan-European payer's perspective, based on prevalence data for UODs for which patented drugs are available and/or for which drugs are in clinical development. Results: A total of 18 drugs under patent protection or orphan drug designation for non-oncological UODs were identified. Furthermore, 29 ultra-orphan drugs for non-oncological diseases under development that have the potential of reaching the market by 2021 were found. Total budget impact over 10 years was estimated to be (sic)15,660 and (sic)4965 million for approved and pipeline ultra-orphan drugs, respectively (total: (sic)20,625 million). Conclusion: The analysis does not support concerns regarding an uncontrolled growth in expenditures for drugs for UODs.

AB - Background/aim: Ultra-orphan diseases (UODs) have been defined by a prevalence of less than 1 per 50,000 persons. However, little is known about budget impact of ultra-orphan drugs. Methods: For analysis, the budget impact analysis (BIA) had a time horizon of 10 years (2012-2021) and a pan-European payer's perspective, based on prevalence data for UODs for which patented drugs are available and/or for which drugs are in clinical development. Results: A total of 18 drugs under patent protection or orphan drug designation for non-oncological UODs were identified. Furthermore, 29 ultra-orphan drugs for non-oncological diseases under development that have the potential of reaching the market by 2021 were found. Total budget impact over 10 years was estimated to be (sic)15,660 and (sic)4965 million for approved and pipeline ultra-orphan drugs, respectively (total: (sic)20,625 million). Conclusion: The analysis does not support concerns regarding an uncontrolled growth in expenditures for drugs for UODs.

KW - budget impact analysis

KW - drugs

KW - Europe

KW - non-oncological diseases

KW - ultra-orphan

KW - TASK-FORCE

KW - RARE

KW - PRINCIPLES

KW - DISORDERS

U2 - 10.1586/14737167.2015.965156

DO - 10.1586/14737167.2015.965156

M3 - Article

VL - 15

SP - 171

EP - 179

JO - Expert Review of Pharmacoeconomics & Outcomes Research

JF - Expert Review of Pharmacoeconomics & Outcomes Research

SN - 1473-7167

IS - 1

ER -